Borderline tumors may have a distinct genetic etiology. »
11/26/13

Because of poor outcomes in mucosal melanoma, studies of systemic therapy are warranted regardless of the extent of disease at presentation. »
09/26/13

Aberrant promoter methylation of P16 in exhaled breath condensate as a new, non-invasive tool for diagnosis and screening program of NSCLC. »
04/21/13

The circadian clock gene Bmal1 is involved in cancer cell proliferation and DNA damage sensitivity. The aim of this study was to explore the effect of Bmal1 on oxaliplatin sensitivity and to determine its clinical significance in colorectal cancer (CRC). »
11/27/13

Chaperone-mediated protein folding in the ER linked to mechanisms underlying oncogenic transformation. »
11/26/13

hPEBP4 is a novel and clinically relevant metastasis accelerator gene in breast cancer. »
02/22/13

Guideline-adherent chemotherapy treatment patterns must carefully consider the definition of treatment eligibility. »
09/12/13

Downregulation of ITIH5 by aberrant DNA hypermethylation may provoke invasive phenotypes in human bladder cancer. »
11/23/13

Given the high vascularity of human bladder cancer and the ability of HSV-TK or endostatin monotherapy to eradicate the tumors, we decided to test a novel combination of cytotoxic and antiangiogenic gene therapy using HSV-TK and endostatin adeno-associated viruses (AAV) in vitro. »
11/27/13

Tamoxifen is widely used to treat hormone-dependent breast cancer, but its therapeutic benefit is limited by the development of drug resistance. Here, we investigated the role of estrogen G-protein coupled receptor 30 (GPR30) on Tamoxifen resistance in breast cancer. »
11/29/13